Progressive retinal atrophy
|Progressive retinal atrophy|
WikiDoc Resources for Progressive retinal atrophy
Evidence Based Medicine
Guidelines / Policies / Govt
Patient Resources / Community
Healthcare Provider Resources
Continuing Medical Education (CME)
Experimental / Informatics
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us  to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Progressive retinal atrophy (PRA) is a group of genetic diseases characterized by degeneration of the retina that occurs bilaterally. It is seen in certain breeds of dogs and more rarely, cats. It causes progressive vision loss culminating in blindness. The condition in nearly all breeds is inherited as an autosomal recessive trait, with the exception of the Siberian Husky (inherited as an X chromosome linked trait) and the Bullmastiff (inherited as an autosomal dominant trait). There is no treatment. PRA is similar to retinitis pigmentosa in humans.
Progressive vision loss in any dog in the absence of glaucoma or cataracts can be an indication of PRA. It usually starts with decreased vision at night, or nyctalopia. Other symptoms include dilated pupils and decreased pupillary light reflex. Fundoscopy to examine the retina will show shrinking of the blood vessels, decreased pigmentation of the nontapetal fundus, increased reflection from the tapetum due to thinning of the retina, and later in the disease a darkened, atrophied optic disc. Secondary cataract formation in the posterior portion of the lens can occur late in the disease. In these cases diagnosis of PRA may require electroretinography (ERG). For many breeds there are specific genetic tests of blood or buccal mucosa for PRA.
Types of PRA
Generalized PRA is the most common type and causes atrophy of all the neural retinal structures. Central progressive retinal atrophy (CPRA) is a different disease from PRA involving the retinal pigment epithelium (RPE), and is also known as retinal pigment epithelial dystrophy (RPED).
Generalized PRA can be divided into either dysplastic disease, where the cells develop abnormally, and degenerative, where the cells develop normally but then undergo a damaging change. PRA can be further divided into affecting either rod or cone cells. Rod cells detect shape and motion, and function in dim light. Cone cells detect color and definition, and function in bright light.
Commonly affected breeds:
- Akita - Symptoms at one to three years old and blindness at three to five years old.
- Miniature longhaired Dachshund - Symptoms at six months old.
- Papillon - Slowly progressive with blindness at seven to eight years old.
- Tibetan Spaniel - Symptoms at three to five years old.
- Tibetan Terrier - Symptoms at less than one year old, often blind by two years old, and cataract formation by four years old.
- Samoyed - Symptoms by three to five years old.
This type of PRA has an early onset of severe vision loss. It is caused by a defect in the gene for cGMP-phosphodiesterase, which leads to retinal levels of cyclic guanosine monophosphate ten times normal.
Rod-cone dysplasia type 1
- Irish Setter - Rod cell response is nearly absent. Night blindness by six to eight weeks old, often blind by one year old.
Rod-cone dysplasia type 2
- Collie - Rod cell response is nearly absent. Night blindness by six weeks old, blind by one to two years old.
Rod-cone dysplasia type 3
- Cardigan Welsh Corgi
- Norwegian Elkhound - Characterized by dysplasia of the rod cell unit and subsequent degeneration of the cone cell unit. Rod cell response is nearly absent. Night blindness by six months old, blind by three to five years old. This has been bred out of this dog.
Early retinal degeneration
- Norwegian Elkhound - Night blindness by six weeks old, blind by twelve to eighteen months old.
This is caused by an abnormal development of both rod and cone cells. Dogs are initially night blind and then progress to day blindness.
- Miniature Schnauzer - Slowly progressive, not seen until two to five years old.
- Belgian Shepherd Dog - Complete blindness by eight weeks old.
- Alaskan Malamute - Temporary loss of vision in daylight (hemeralopia) at eight to ten weeks old. There is a purely rod cell retina by four years old.
Progressive rod-cone degeneration (PRCD)
This is a disease with normal rod and cone cell development but late onset degeneration of the rod cells that progresses to the cone cells. It is inherited as an autosomal recessive trait and has been linked to the ninth canine chromosome.
- Poodle - Night blindness by three to five years old, blind by five to seven years old.
- English Cocker Spaniel - Occurs late in life, usually at four to eight years old.
- American Cocker Spaniel - Night blindness by three to five years old, blind one to two years later.
- Labrador Retriever - Night blindness by four to six years old, blind at six to eight years old.
- Portuguese Water Dog
- Chesapeake Bay Retriever
- Australian Cattle Dog
- Nova Scotia Duck Tolling Retriever
This condition is linked to the X chromosome.
- Siberian Husky - Night blindness by two to four years old.
- Samoyed - More severe disease than the Husky.
- Bullmastiff - Inherited as an autosomal dominant trait due to a mutation in the gene for rhodopsin.
- Abyssinian - Two forms exist. One is inherited as an autosomal dominant trait and has an early age onset. The other is inherited as an autosomal recessive trait and has a middle age onset.
- Early onset PRA has also been reported in the domestic shorthaired cat and Persian. The Siamese also likely has a hereditary form of PRA. Despite belief among breeders to the contrary, there is apparently no link between coat color in Persians and the development of PRA.
Central progressive retinal atrophy (CPRA)
CPRA is also known as retinal pigment epithelial dystrophy (RPED). The cause of this condition is the loss of the retinal pigment epithelium's ability to effectively process the photoreceptor outer segment (POS) and subsequent accumulation of POS material in the RPE and loss of function. The loss of function of the RPE leads to photoreceptor degeneration. Vitamin E deficency may play a role in the development of CPRA. It is characterized by accumulation of pigment spots in the retina surrounded by retinal atrophy and a mottled appearance of the pigmented nontapetal fundus. The pigmented spots eventually coalesce and fade as the atrophy of the retina increases. It is an inherited condition (in the Labrador Retriever it is inherited as an autosomal dominant trait with variable penetrance). CPRA occurs in older dogs. Peripheral vision is retained for a long time. Vision is better in low light and better for moving or distant objects. Not all affected dogs go blind. Secondary cataracts are common.
Commonly affected breeds
- Labrador Retriever
- Golden Retriever
- Border Collie
- Shetland Sheepdog
- English Cocker Spaniel
- English Springer Spaniel
- Chesapeake Bay Retriever
- Cavalier King Charles Spaniel
- Briard - has an especially high frequency.
- It can also, but very rarely, be found in the Papillon.
Hereditary retinal dysplasia
There is another retinal disease in Briards known as hereditary retinal dysplasia. These dogs are night blind from birth, and day vision varies. Puppies affected often have nystagmus. It is also known as lipid retinopathy.
- "Inherited Retinopathies". The Merck Veterinary Manual. 2006. Retrieved 2007-03-10.
- Petersen-Jones, Simon M. (2003). "Progressive Retinal Atrophy: An Overview". Proceedings of the 28th World Congress of the World Small Animal Veterinary Association. Retrieved 2007-03-10.
- Gelatt, Kirk N. (ed.) (1999). Veterinary Ophthalmology (3rd ed. ed.). Lippincott, Williams & Wilkins. ISBN 0-683-30076-8.
- Bedford, Peter (2006). "Hereditary Retinal Diseases" (PDF). Proceedings of the 31st World Congress of the World Small Animal Veterinary Association. Retrieved 2007-03-10.
- Giuliano E, van der Woerdt A (1999). "Feline retinal degeneration: clinical experience and new findings (1994-1997)". J Am Anim Hosp Assoc. 35 (6): 511–4. PMID 10580912.
- Rah H, Maggs D, Lyons L (2006). "Lack of genetic association among coat colors, progressive retinal atrophy and polycystic kidney disease in Persian cats". J Feline Med Surg. 8 (5): 357–60. PMID 16777456.
- Davidson M, Geoly F, Gilger B, McLellan G, Whitley W (1998). "Retinal degeneration associated with vitamin E deficiency in hunting dogs". J Am Vet Med Assoc. 213 (5): 645–51. PMID 9731258.
Cost Effectiveness of Progressive retinal atrophy
| group5 = Clinical Trials Involving Progressive retinal atrophy | list5 = Ongoing Trials on Progressive retinal atrophy at Clinical Trials.gov • Trial results on Progressive retinal atrophy • Clinical Trials on Progressive retinal atrophy at Google
| group6 = Guidelines / Policies / Government Resources (FDA/CDC) Regarding Progressive retinal atrophy | list6 = US National Guidelines Clearinghouse on Progressive retinal atrophy • NICE Guidance on Progressive retinal atrophy • NHS PRODIGY Guidance • FDA on Progressive retinal atrophy • CDC on Progressive retinal atrophy
| group7 = Textbook Information on Progressive retinal atrophy | list7 = Books and Textbook Information on Progressive retinal atrophy
| group8 = Pharmacology Resources on Progressive retinal atrophy | list8 = AND (Dose)}} Dosing of Progressive retinal atrophy • AND (drug interactions)}} Drug interactions with Progressive retinal atrophy • AND (side effects)}} Side effects of Progressive retinal atrophy • AND (Allergy)}} Allergic reactions to Progressive retinal atrophy • AND (overdose)}} Overdose information on Progressive retinal atrophy • AND (carcinogenicity)}} Carcinogenicity information on Progressive retinal atrophy • AND (pregnancy)}} Progressive retinal atrophy in pregnancy • AND (pharmacokinetics)}} Pharmacokinetics of Progressive retinal atrophy •
| group9 = Genetics, Pharmacogenomics, and Proteinomics of Progressive retinal atrophy | list9 = AND (pharmacogenomics)}} Genetics of Progressive retinal atrophy • AND (pharmacogenomics)}} Pharmacogenomics of Progressive retinal atrophy • AND (proteomics)}} Proteomics of Progressive retinal atrophy
| group10 = Newstories on Progressive retinal atrophy | list10 = Progressive retinal atrophy in the news • Be alerted to news on Progressive retinal atrophy • News trends on Progressive retinal atrophy
| group11 = Commentary on Progressive retinal atrophy | list11 = Blogs on Progressive retinal atrophy
| group12 = Patient Resources on Progressive retinal atrophy | list12 = Patient resources on Progressive retinal atrophy • Discussion groups on Progressive retinal atrophy • Patient Handouts on Progressive retinal atrophy • Directions to Hospitals Treating Progressive retinal atrophy • Risk calculators and risk factors for Progressive retinal atrophy
| group13 = Healthcare Provider Resources on Progressive retinal atrophy | list13 = Symptoms of Progressive retinal atrophy • Causes & Risk Factors for Progressive retinal atrophy • Diagnostic studies for Progressive retinal atrophy • Treatment of Progressive retinal atrophy
| group14 = Continuing Medical Education (CME) Programs on Progressive retinal atrophy | list14 = CME Programs on Progressive retinal atrophy
| group17 = Informatics Resources on Progressive retinal atrophy | list17 = List of terms related to Progressive retinal atrophy